Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rakovina Therapeutics Inc ( (TSE:RKV) ) has issued an announcement.
Rakovina Therapeutics Inc. and Variational AI have expanded their collaboration to accelerate optimization of Rakovina’s kt-5000 series of ATR inhibitors, an emerging class of cancer drugs targeting a key DNA damage response regulator implicated in solid tumors such as ovarian, breast and prostate cancers. Under a new agreement, Variational AI will use its Enki generative AI platform to iteratively refine previously identified kt-5000 leads, while Rakovina retains decision-making over which compounds move into lab testing, with the shared goal of identifying a clinical candidate in months instead of years and addressing shortcomings of existing ATR inhibitors, including improving potency, selectivity and central nervous system penetration, thereby potentially strengthening Rakovina’s competitive position in AI-enabled oncology drug discovery and speeding its path toward human trials.
More about Rakovina Therapeutics Inc
Rakovina Therapeutics Inc. is a Vancouver-based biopharmaceutical research company focused on developing innovative cancer treatments that target the DNA damage response. Leveraging AI-driven platforms such as Deep-Docking and Variational AI’s Enki, the company is building a pipeline of small-molecule DNA-damage response inhibitors with the aim of advancing one or more candidates into human clinical trials in partnership with pharmaceutical companies.
Average Trading Volume: 39,107
Technical Sentiment Signal: Sell
Current Market Cap: C$2.33M
Find detailed analytics on RKV stock on TipRanks’ Stock Analysis page.